Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord

Strategies for spinal cord injury repair are limited, in part, by poor drug delivery techniques. A novel drug delivery system (DDS) is being developed in our laboratory that can provide localized release of growth factors from an injectable gel. The gel must be fast-gelling, non-cell adhesive, degradable, and biocompatible as an injectable intrathecal DDS. A gel that meets these design criteria is a blend of hyaluronan and methylcellulose (HAMC). Unlike other injectable gels, HAMC is already at the gelation point prior to injection. It is injectable due to its shear-thinning property, and its get strength increases with temperature. In vivo rat studies show that HAMC is biocompatible within the intrathecal space for 1 month, and may provide therapeutic benefit, in terms of behavior, as measured by the Basso, Beattie and Bresnahan (BBB) locomotor scale, and inflammation. These data suggest that HAMC is a promising gel for localized delivery of therapeutic agents to the injured spinal cord. (c) 2005 Elsevier Ltd. All rights reserved.